Usefulness of Cytokeratin-18M65 in Diagnosing Non-Alcoholic Steatohepatitis in Japanese Population

Objective: The aim of this study was to evaluate cytokeratin-18M65 (CK-18M65) for distinguishing between simple steatosis (SS) and non-alcoholic steatohepatitis (NASH) against healthy individuals (HIs) in Japanese population. Methods: The serum from 24 HIs, 21 patients with SS and 20 patients with NASH were examined. Serum CK-18M65 was measured by enzyme-linked immunosorbent assay. Results: Aspartate aminotransferase was significantly different between NASH patients and HIs with p < 0.0001 (SS patients and HIs: p < 0.0001), as was alanine aminotransferase between NASH patients and HIs with p < 0.0001 (SS patients and HIs: p < 0.0001). Serum CK-18M65 increased in a stepwise fashion in HIs and also in SS and NASH patients. Multivariate logistic regression analysis revealed that NASH could be diagnosed with the use of CK-18M65 alone (p = 0.0285, OR 1.0038, 95% CI 1.0004-1.0073). At the optimal cut-off level of 548 U/l, CK-18M65 had an AUC value of 0.7369, 60.00% sensitivity and 85.70% specificity. In patients with NASH, no significant difference was observed between low fibrosis (Stage 0-1, 794.30 ± 454.41, n = 10) and high fibrosis (Stage 2-3, 809.70 ± 641.43, n = 10; p = 0.5967) and between slight steatosis (<33%, 512.89 ± 229.65, n = 9) and moderate steatosis (≥33%, 655.13 ± 480.78, n = 32) in patients with non-alcoholic fatty liver disease (NAFLD; p = 0.7647) with the use of CK-18M65. Conclusion: Serum CK-18M65 distinguished NASH from SS, but could not assess the severity of steatosis in NAFLD patients or the grade of fibrosis in NASH patients in Japanese population.

[1]  A. Nakajima,et al.  Microbiota and nonalcoholic steatohepatitis , 2013, Seminars in Immunopathology.

[2]  Caiyan Zhao,et al.  Cytokeratin 18, Alanine Aminotransferase, Platelets and Triglycerides Predict the Presence of Nonalcoholic Steatohepatitis , 2013, PloS one.

[3]  D. Torres,et al.  Features, diagnosis, and treatment of nonalcoholic fatty liver disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  C. Flask,et al.  Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. , 2012, Journal of applied physiology.

[5]  V. Wong,et al.  Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. , 2012, Journal of hepatology.

[6]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[7]  K. Cusi,et al.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. , 2012, Gastroenterology.

[8]  Bernhard Vaske,et al.  Prospective biopsy‐controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis , 2012, Hepatology.

[9]  T. Saibara,et al.  A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease , 2011, Journal of Gastroenterology.

[10]  M. Hussain,et al.  Serum Levels of CK18 M30 and Leptin Are Useful Predictors of Steatohepatitis and Fibrosis in Paediatric NAFLD , 2010, Journal of pediatric gastroenterology and nutrition.

[11]  Vincent Wai-Sun Wong,et al.  Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.

[12]  A. Feldstein,et al.  Cytokeratin‐18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study , 2009, Hepatology.

[13]  P. Schauer,et al.  Triglyceride Levels and Not Adipokine Concentrations Are Closely Related to Severity of Nonalcoholic Fatty Liver Disease in an Obesity Surgery Cohort , 2009, Obesity.

[14]  P. Schauer,et al.  Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  J. Carew,et al.  Cytokeratin 18, a Marker of Cell Death, Is Increased in Children With Suspected Nonalcoholic Fatty Liver Disease , 2008, Journal of pediatric gastroenterology and nutrition.

[16]  E. Vittinghoff,et al.  A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients , 2008, Hepatology.

[17]  A. Baranova,et al.  A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH) , 2008, Obesity surgery.

[18]  M. Tsutsumi,et al.  Usefulness of a Combined Evaluation of the Serum Adiponectin Level, HOMA-IR, and Serum Type IV Collagen 7S Level to Predict the Early Stage of Nonalcoholic Steatohepatitis , 2007, The American Journal of Gastroenterology.

[19]  A. Feldstein,et al.  Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future , 2007, Hepatology.

[20]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[21]  V. Wong,et al.  Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  K. Birkeland,et al.  Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. , 2006, Journal of hepatology.

[23]  G. Farrell,et al.  Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.

[24]  Hiroyuki Kaneda,et al.  The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[25]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[26]  M. Manns,et al.  Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury , 2004, Hepatology.

[27]  F. Chan,et al.  Clinical and histological features of non‐alcoholic fatty liver disease in Hong Kong Chinese , 2004, Alimentary pharmacology & therapeutics.

[28]  Erick M Remer,et al.  The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[29]  F. Degos,et al.  Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey , 2000, Hepatology.